HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 -- HUTCHMED Limited today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new...

Related Keywords

Beijing , China , Spain , Tianjin , Shanghai , Oslo , Norway , Wuhan , Hubei , Ying Qian , Jiangxi , Valencia , Carabobo , Venezuela , Cheng Mei , Guangdong , Peking , Hong Kong , Tongji , Sichuan , Texas , United States , Houston , Madrid , Huazhong , Chinese , Renchi Yang , Pau Montesinos , Zhou Yi , Atholl Tweedie , Mingci Cai , Hall Mallo , Xiaojun Huang , Fengkui Zhang , Xiaofan Liu , Ben Atwell Alex Shaw , Waleed Ghanima , Tongji Medical College , Shanghai Jiao Tong University School Of Medicine , European Hematology Association , Linkedin , Nasdaq , Chinese Academy Of Medical Sciences , China Limited , University People Hospital , Union Hospital , Huazhong University Of Science , Institute Of Hematology , University Of Oslo , Stock Exchange Of Hong Kong , Exchange Commission , University Of Texas Md Anderson Cancer Center , Hybrid Congress , Immune Thrombocytopenia , Syk Inhibitor Sovleplenib , Adult Patients , Primary Immune Thrombocytopenia , Placebo Controlled Phase , Blood Diseases Hospital , Chinese Academy , Medical Sciences , Warm Antibody Autoimmune Hemolytic Anemia , Prior Lines , Subgroup Analysis , Huazhong University , Heavily Pre Treated Hodgkin Lymphoma , Cancer Center , Final Result , Dose Expansion , University People , Advanced Acute Myeloid Leukemia , Isocitrate Dehydrogenase , Preliminary Results , Dose Escalation , Shanghai Jiao Tong University School , Escalation Study , Third Generation , Highly Selective , Chinese Patients , Preliminary Efficacy , Syk Inhibitor , Adult Subjects , Securities Litigation Reform Act , Stock Exchange , Hong Kong Limited , Alex Shaw ,